Skip to content

Press Releases

Lorem ipsum dolor sit amet

Criterium, Inc. joins with Hemostemix to Advance Clinical Trial Preparation
Hemostemix, a clinical-stage Canadian-Israeli company developing innovative blood-derived cell therapies for severe medical conditions, announced today the kick-off of a services collaboration with Criterium Inc. as its clinical research organization (CRO) for the company’s phase 2 clinical trial in critical limb ischemia.
Criterium Inc. is proud to be the CRO of record for AtoxBio’s ATB-103 Study
This is a study to evaluate the safety and pharmacokinetics profile of different doses of AB‐103 administered to patients diagnosed with Necrotizing Soft Tissue Infections that are scheduled for an urgent surgical intervention as part of their standard of care.
Wockhardt launches generic version of Rhinitis drug Flonase® nasal spray
Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 50 mcg nasal spray of Fluticasone which is used in treatment of allergic rhinitis.
Criterium Announces New Acquisition – Former Aptium Oncology Cancer Consortium Finds a New Home
Criterium, Inc., a full-service, global CRO, is pleased to announce the acquisition of the former Aptium Oncology’s CORE Science Solutions (CSS) Cancer Consortium Groups consisting of AGICC and AMyC as the newest members of Criterium’s Pharma services companies.